Targeted Oncology Staff | Authors


Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL

December 06, 2021

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.